The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ASND | +56.67% | +20.72% | +3.84% | +966% |
| S&P | +14.08% | +93.57% | +14.12% | +242% |
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
A bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day.
A critical response letter from the FDA means hope remains for the company's hypoparathyroidism therapy candidate.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $179.27M | 362.6% |
| Gross Profit | $139.23M | 473.5% |
| Gross Margin | 77.67% | 15.0% |
| Market Cap | $10.42B | 35.0% |
| Net Income | -$44.07M | 62.6% |
| EBITDA | -$55.18M | 60.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $579.94M | 109.2% |
| Accounts Receivable | $129.65M | 146.1% |
| Inventory | 356.1 | 32.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $387.59M | 65.1% |
| Short Term Debt | $542.73M | 11.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -28.11% | 33.8% |
| Return On Invested Capital | -82.33% | -23.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13.22M | 80.0% |
| Operating Free Cash Flow | -$8.48M | 87.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -24.88 | -75.75 | -85.21 | -50.82 | 67.17% |
| Price to Sales | 24.24 | 21.02 | 23.74 | 19.52 | -14.35% |
| Price to Tangible Book Value | -24.56 | -72.68 | -82.08 | -49.80 | 66.76% |
| Enterprise Value to EBITDA | -86.45 | 1649.23 | -92.57 | -195.46 | 228.11% |
| Return on Equity | -867.6% | - | |||
| Total Debt | $880.19M | $887.03M | $915.22M | $930.32M | 29.05% |
No podcast episodes available.
ASND earnings call for the period ending September 30, 2021.
ASND earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
